Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha/beta hydrolase domain-containing protein 6 (ABHD6) is a membrane-bound serine hydrolase that serves as a key regulator of the endocannabinoid system by hydrolyzing 2-arachidonoylglycerol (2-AG), the most abundant endogenous ligand for cannabinoid receptors (UniProt, Q9BV71). Although monoacylglycerol lipase (MAGL) accounts for the majority of 2-AG degradation in the brain, ABHD6 provides localized control of 2-AG signaling at the synapse, particularly at the postsynaptic membrane where it acts as a gatekeeper for CB1 receptor activation (PubMed, 22403446). Beyond the central nervous system, ABHD6 is highly expressed in pancreatic beta cells and liver tissue, where it regulates insulin secretion and lipid accumulation by modulating monoacylglycerol levels (PubMed, 24439591).
Pharmacological inhibition of ABHD6 has emerged as a promising strategy for treating a variety of conditions, including neuroinflammatory diseases like multiple sclerosis and metabolic disorders such as type 2 diabetes (PubMed, 26949163). By elevating 2-AG levels, ABHD6 inhibitors like WWL70 and KT182 exert anti-inflammatory and neuroprotective effects in preclinical models (PubChem, CID 25154897). However, the therapeutic application of ABHD6 inhibitors requires careful consideration of selectivity within the serine hydrolase superfamily to avoid unintended metabolic or neurological side effects. Current research continues to explore its potential as a target for modulating both central neurotransmission and peripheral energy homeostasis.
Inhibition of ABHD6 enzymatic activity to increase levels of 2-arachidonoylglycerol (2-AG), thereby enhancing cannabinoid receptor signaling.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha/beta hydrolase domain-containing protein 6 (ABHD6).